Search results
Showing 1451 to 1500 of 3041 results for all
In development Reference number: GID-TA11504 Expected publication date: 28 January 2026
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
This quality standard covers managing intravenous (IV) fluid therapy safely and effectively for adults in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS66Show all sections
Sections for QS66
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (IPG427)
Evidence-based recommendations on percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation. This involves using a probe attached to a balloon catheter to freeze tissue in one of the chambers on the left side of the heart.
View recommendations for IPG427Show all sections
Sections for IPG427
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
Video laryngoscopes to help intubation in people with difficult airways (MIB167)
NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .
This guide describes the process NICE uses to develop NICE quality standards
In development Reference number: GID-TA11566 Expected publication date: TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)
NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .
This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
In development Reference number: GID-TA11613 Expected publication date: TBC
In development Reference number: GID-TA11230 Expected publication date: 22 April 2026
Optilume for treating recurrent bulbar urethral strictures (HTG649)
Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Awaiting development Reference number: GID-HST10067 Expected publication date: TBC
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Kidney conditions: CKD urine albumin:creatinine ratio (IND144)
This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109
Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)
doses you have left. There are lots of types of dry powder inhaler and not all are shown here. No Soft mist inhalers (SMIs) You press a...
Thopaz+ portable digital system for managing chest drains (HTG465)
Evidence-based recommendations on Thopaz+ for managing chest drains.
Evidence-based recommendations on Kurin Lock for blood culture collection.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
In development Reference number: GID-TA10575 Expected publication date: 22 April 2026
In development Reference number: GID-TA11140 Expected publication date: TBC
In development Reference number: GID-TA11379 Expected publication date: TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
In development Reference number: GID-TA10752 Expected publication date: 10 July 2026
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
In development Reference number: GID-TA11767 Expected publication date: 04 November 2026
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448
In development Reference number: GID-TA11564 Expected publication date: 22 July 2026
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026